• GENESIS Biomed closes 2025 as its best year ever, with strong growth compared to 2024: 506 projects (+26.5%) and 323 customers (+43.6%).

• Increased investment mobilised for the biomedical ecosystem, reaching €86M in capital raised in 2025 (+7.5% vs. 2024), maintaining a 100% organic growth model and presence in three locations.

• Significantly strengthens its collaboration in projects with multinationals and large companies in the health, pharmaceutical and industrial sectors.

• Reinforces its role as a driving force in the sector with active participation in BIOSPAIN 2025 (sponsorship and round table on AI in health) and the 2025 GENESIS Biomed Annual Conference at the Barcelona Science Park, as spaces for connecting innovation, investment and industry.

• Promotes entrepreneurship and transfer to the market, with the launch of the CEO Academy and its participation in high-impact milestones such as the acquisitions of AptaTargets by Merck and CellsIA, acquired by Laboratorios ROVI.

GENESIS Biomed closes 2025 consolidating a trajectory of sustained growth and real impact in healthcare innovation. Compared to 2024, the company will significantly increase its activity, reinforcing its position as a driving force in the national biomedical ecosystem. The company’s performance indicators show a quantitative leap in 2025 compared to the previous year. In terms of cumulative activity, GENESIS Biomed reached 506 consulting projects compared to 400 in 2024 (+26.5%), and expanded its client base to 323 clients compared to 225 (+43.6%). In parallel, the consultancy firm continues to strengthen one of its most visible contributions to the ecosystem: the ability to mobilise investment for biomedical projects. In 2025, GENESIS Biomed will reach €86M in capital raised (vs. €80M in 2024; +7.5%). This growth will be achieved while maintaining the consistency of the model: 100% organic growth, presence in three sites and a consolidated operational base. In addition, the consultancy increased its cumulative turnover to €11M (vs. €9M in 2024; +22.2%).

In the area of investment and operational support, GENESIS Biomed maintains two managed vehicles, with €3.5M associated and a total of 20 investments made, reinforcing an end-to-end vision that combines strategic consultancy with a practical knowledge of investment logic and corporate operations.

Reinforcement of the collaborative role with multinationals and large companies

GENESIS Biomed has significantly strengthened its collaboration in projects with multinational and large companies in the health, pharma and industrial sectors, consolidating its position as a benchmark partner in this field. In 2025 the consultancy firm has worked actively with leading groups such as Novartis, AstraZeneca and Roche, as well as with top industrial and technological companies such as Grifols, Abbott, Siemens Healthineers and Telefónica. These partnerships reflect our ability to add value in complex environments, combining strategic vision, deep industry knowledge and expertise in innovation and growth. The diversity and weight of these organisations is evidence of the trust placed in GENESIS Biomed to support high-impact projects, both nationally and internationally.

Role as a driving force in the ecosystem

Beyond internal growth, throughout 2025 GENESIS Biomed has continued to deepen its role as a link between entrepreneurs, research centres, investors and large companies. The firm has reinforced this role through the leadership of discussion spaces and active participation in industry events.

For this reason, and being aware of the importance of the biomedical ecosystem, GENESIS Biomed was a sponsor of BIOSPAIN 2025, the largest biotechnology event organised by a national bioindustry association in Europe. During this edition, the company promoted the round table “AI in the health sector: driving innovation, investment and regulation”, promoting debate on topical and high-impact issues for the biomedical sector. Along the same lines, GENESIS Biomed held its Annual Conference at the Barcelona Science Park (PCB) as a space for meeting, reflection and alignment of the ecosystem, with the participation of investors, entrepreneurs, the medtech, pharmaceutical and Digital Health industry.

Role as a driver of entrepreneurship

GENESIS Biomed’s commitment to promoting entrepreneurship is reflected in the creation of the “CEO Academy” programme for 2025, an initiative that seeks to train researchers in leadership skills to play the role of CEO and facilitate the creation and consolidation of future spin-offs and start-ups in the country.

On the other hand, true to its founding principles, GENESIS Biomed continues to support start-ups and spin-offs in different business areas to advance their developments and accelerate their arrival on the market. An example of this is its contribution to the strategic development of AptaTargets, which in May 2025 signed a licensing agreement with Merck for the clinical development and global commercialisation of ApTOLL, a candidate with neuroprotective effect for the treatment of ischaemic stroke. Another example was the advice on the valuation of Cells IA Technologies and its portfolio in pathological anatomy using AI, work that helped facilitate the majority acquisition by Laboratorios ROVI, which invested close to 4 million euros to reach a 94.995% stake.

With these results, GENESIS Biomed reaffirms its position as a benchmark consultancy for biomedical innovation in Spain, capable of operating with technical rigour, business vision and understanding of the ecosystem, while also contributing to the debate and promotion of the biomedical sector.